A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in <i>BRCA</i> non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
Yong Jae Lee, Myong Cheol Lim, Byoung‐Gie Kim, Natalie Y.L. Ngoi, Chel Hun Choi, Sang‐Yoon Park, David S.P. Tan, Yunjung Go, Jung‐Yun Lee
Abstract
BACKGROUND: wild-type patients with platinum-sensitive recurrent ovarian cancer. METHODS: wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04361370, Clinical Research Information Service Identifier: KCT0005144.